Orchestra BioMed (NASDAQ:OBIO) Releases Earnings Results

Orchestra BioMed (NASDAQ:OBIO) posted its quarterly earnings data on Thursday. The company reported $0.26 earnings per share (EPS) for the quarter, FiscalAI reports. The firm had revenue of $30.92 million for the quarter. Orchestra BioMed had a negative net margin of 2,665.05% and a negative return on equity of 320.09%.

Orchestra BioMed Trading Down 3.0%

Shares of NASDAQ:OBIO opened at $4.46 on Thursday. Orchestra BioMed has a 52-week low of $2.20 and a 52-week high of $5.42. The stock has a market cap of $251.83 million, a price-to-earnings ratio of -2.45 and a beta of 0.56. The company has a quick ratio of 4.72, a current ratio of 4.73 and a debt-to-equity ratio of 0.32. The business has a 50-day moving average price of $4.19 and a 200-day moving average price of $3.83.

Wall Street Analyst Weigh In

A number of analysts recently commented on OBIO shares. Chardan Capital reiterated a “buy” rating and issued a $20.00 target price on shares of Orchestra BioMed in a research note on Thursday, November 13th. TD Cowen started coverage on shares of Orchestra BioMed in a research note on Wednesday, December 10th. They set a “buy” rating on the stock. Finally, Barclays lifted their price objective on shares of Orchestra BioMed from $11.00 to $12.00 and gave the stock an “overweight” rating in a research note on Friday, January 9th. One research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Orchestra BioMed currently has an average rating of “Moderate Buy” and an average price target of $13.80.

Institutional Investors Weigh In On Orchestra BioMed

A number of large investors have recently bought and sold shares of the company. Catalyst Funds Management Pty Ltd purchased a new position in Orchestra BioMed during the 2nd quarter worth approximately $31,000. China Universal Asset Management Co. Ltd. acquired a new stake in shares of Orchestra BioMed in the fourth quarter worth $38,000. Creative Planning acquired a new stake in shares of Orchestra BioMed in the second quarter worth $40,000. XTX Topco Ltd purchased a new position in shares of Orchestra BioMed during the second quarter worth $45,000. Finally, Jane Street Group LLC acquired a new position in Orchestra BioMed during the second quarter valued at $50,000. Hedge funds and other institutional investors own 53.20% of the company’s stock.

Orchestra BioMed Company Profile

Orchestra BioMed, Inc (NASDAQ: OBIO) is a clinical‐stage biopharmaceutical company dedicated to developing targeted therapies for inflammatory, fibrotic and oncologic diseases. The company’s research focuses on novel small-molecule programs designed to address high‐unmet-need conditions by leveraging proprietary prodrug and targeted inhibitor platforms. Orchestra BioMed’s pipeline includes lead candidates such as OBI-3424, a prodrug activated by AKR1C3 for the treatment of select solid tumors, and next-generation modulators aimed at suppressing pathological inflammation and fibrosis.

Orchestra BioMed conducts early‐ and mid-stage clinical studies in North America, working closely with key opinion leaders and academic centers to advance its programs.